A new report forecasts that the global multiple sclerosis drugs market will generate $23.2 billion in 2020. That revenue forecast and others appear in Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026: Revenue Forecasts for Leading Submarkets including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif, published by visiongain in June 2016. That company is a business information publisher and consultancy based in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), and 2.5 million people around the world suffer from the condition. MS represents a lucrative pharmaceutical market, with a range of blockbuster therapies that are able to charge premium prices.”

“However, most of these leading therapies will face patent expiry within the next ten years, representing a crucial period for this market, and it remains to be seen whether it can maintain growth in the face of generic and biosimilar competition. Fortunately, for the market and for patients, the drugs pipeline contains many exciting therapies which could represent future blockbusters and market leaders.”

Visiongain’s new report shows revenue forecasts to 2026 for 10 leading marketed drugs and three promising candidates in the R&D pipeline:

• Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
• Tecfidera (dimethyl fumarate) by Biogen
• Avonex (interferon beta-1a) by Biogen
• Gilenya (fingolimod) by Novartis
• Rebif (interferon beta-1a) by Merck KGaA
• Tysabri (natalizumab) by Biogen
• Betaseron/Betaferon (interferon beta-1b) by Bayer
• Aubagio (teriflunomide) by Sanofi
• Plegridy (peginterferon beta-1a) by Biogen
• Lemtrada (alemtuzumab) by Sanofi
• Ocrelizumab (Ocrevus / RG1594) by Roche
• Ozanimod by Celgene
• Zinbryta (daclizumab high-yield process) by Biogen and AbbVie.

Visiongain’s study also gives revenue predictions to 2026 for five therapeutic submarkets:

• Monoclonal antibodies (mAbs)
• S1PR modulators
• Interferons
• Other immunomodulators
• Other agents.

That multilevel investigation also shows revenue forecasts to 2026 for 10 leading national markets for multiple sclerosis drugs:

• US
• Japan
• Canada
• Germany, France, UK, Italy and Spain
• India and China.

Visiongain’s new report discusses trends that will stimulate sales expansion over the next ten years, as well as forces that will limit revenues. Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.